Silibinin and non-melanoma skin cancers

10.1016/j.jtcme.2020.02.003

Ram Raj Prasad；Sandeep Paudel；Komal Raina；Rajesh Agarwal

Squamous cell carcinoma ； Basal cell carcinoma ； Photocarcinogenesis ； Hedgehog pathway ； Cyclobutane pyrimidine dimers

Journal of Traditional and Complementary Medicine

10卷3期（2020 / 05 / 01）

236 - 244

英文

Skin is the largest human organ that shields the inner body from contact with xenobiotic and genotoxic agents, and in this process, the skin's cellular genome faces continuous stress due to direct exposure to these noxious factors. Accumulation of genetic stress results in genomic alterations leading to undesirable gene or protein alteration/expression in skin cells, which eventually causes the formation of non-melanoma skin cancers (NMSCs). Ultraviolet B (UVB) radiation from sun is the most prominent factor contributing to ~5 million skin cancer cases (which are mostly NMSCs) in the United States (US) and western countries. UVB exposure causes aberrations in a range of biochemical and molecular pathways such as: thymine dimer formation, DNA damage, oxidative stress, inflammatory responses, altered cellular signaling, which ultimately contribute to the development of NMSCs. The focus of this review is to summarize the protective and preventive potential of silymarin and/or silibinin against UVB-induced NMSC in pre-clinical skin cancer studies. Over two decades of research has shown the strong potential of silibinin, a biologically active flavonolignan (crude form Silymarin) derived from milk thistle plant, against a wide range of cancers, including NMSCs. Silibinin protects against UVB-induced thymine dimer formation and in turn promotes DNA repair and/or initiates apoptosis in damaged cells via an increase in p53 levels. Additionally, silibinin has shown strong efficacy against NMSCs via its potential to target aberrant signaling pathways, and induction of anti-inflammatory responses. Overall, completed comprehensive studies suggest the potential use of silibinin to prevent and/or manage NMSCs in humans.

1. Agarwal, R,Katiyar, SK,Lundgren, DW,Mukhtar, H(1994).Inhibitory effect of silymarin, an anti-hepatotoxic flavonoid, on 12- O -tetradecanoylphorbol-13-acetate-induced epidermal ornithine decarboxylase activity and mRNA in SENCAR mice.Carcinogenesis,15(6),1099-1103.
2. Apalla, Z,Nashan, D,Weller, RB,Castellsagué, X(2017).Skin cancer: epidemiology, disease burden, pathophysiology, diagnosis, and therapeutic approaches.Dermatol Ther,7,5-19.
3. Becker-Schiebe, M,Mengs, U,Schaefer, M,Bulitta, M,Hoffmann, W(2011).Topical use of a silymarin-based preparation to prevent radiodermatitis: results of a prospective study in breast cancer patients.Strahlenther Onkol,187(8),485-491.
4. Berman, B,Cockerell, CJ,Zografos, P(2013).Pathobiology of actinic keratosis: ultraviolet-dependent keratinocyte proliferation.J Am Acad Dermatol,68(1),10-19.
5. Blumenthal, M,Goldberg, ABJ(2000).Herbal Medicines: Expanded Commission E Monographs.American Botanical Council.
6. Bradford, PT,Goldstein, AM,Tamura, D(2011).Cancer and neurologic degeneration in xeroderma pigmentosum: long term follow-up characterises the role of DNA repair.J Med Genet,48(3),168-176.
7. Brechbiel, J,Miller-Moslin, K,Adjei, AA(2014).Crosstalk between hedgehog and other signaling pathways as a basis for combination therapies in cancer.Canc Treat Rev,40(6),750-759.
8. Chernock, RD(2012).Morphologic features of conventional squamous cell carcinoma of the oropharynx: "keratinizing" and "nonkeratinizing" histologic types as the basis for a consistent classification system.Head Neck Pathol,6(1),41-47.
9. Collins, L,Asfour, L,Stephany, M,Lear, JT,Stasko, T(2019).Management of nonmelanoma skin cancer in transplant recipients.Clin Oncol,31(11),779-788.
10. De Gruijl, FR(2000).Photocarcinogenesis: UVA vs UVB.Methods Enzymol,319,359-366.
11. Deep, G,Agarwal, R(2010).Antimetastatic efficacy of silibinin: molecular mechanisms and therapeutic potential against cancer.Canc Metastasis Rev,29(3),447-463.
12. Dhanalakshmi, S,Agarwal, C,Singh, RP,Agarwal, R(2005).Silibinin up-regulates DNA-protein kinase-dependent p53 activation to enhance UVB-induced apoptosis in mouse epithelial JB6 cells.J Biol Chem,280(21),20375-20383.
13. Dhanalakshmi, S,Mallikarjuna, GU,Singh, R,Agarwal, R(2004).Dual efficacy of silibinin in protecting or enhancing ultraviolet B radiation-caused apoptosis in HaCaT human immortalized keratinocytes.Carcinogenesis,25(1),99-106.
14. Dhanalakshmi, S,Mallikarjuna, GU,Singh, RP,Agarwal, R(2004).Silibinin prevents ultraviolent radiation-caused skin damages in SKH-1 hairless mice via a decrease in thymine dimer positive cells and an up-regulation of p53-p21/Cip1 in epidermis.Carcinogenesis,25(8),1459-1465.
15. Dheeraj, A,Rigby, CM,O’Bryant, CL(2017).Silibinin treatment inhibits the growth of hedgehog inhibitor-resistant basal cell carcinoma cells via targeting EGFRMAPK-akt and hedgehog signaling.Photochem Photobiol,93(4),999-1007.
16. Didona, D,Paolino, G,Bottoni, U,Cantisani, C(2018).Non melanoma skin cancer path-ogenesis overview.Biomedicines,6(1),1-15.
17. Dotto, GP,Rustgi, AK(2016).Squamous cell cancers: a unified perspective on biology and genetics.Canc Cell,29(5),622-637.
18. Flora, K(1998).Milk thistle (Silybum marianum) for the therapy of liver disease.Am J Gastroenterol,93(2),139-143.
19. Godar, DE(1999).UVA1 radiation triggers two different final apoptotic pathways.J Invest Dermatol,112(1),3-12.
20. Gruijl, FR,Rebel, H(2008).Early events in UV carcinogenesis-DNA damage, target cells and mutant p53 foci.Photochem Photobiol,84(2),382-387.
21. Gu, M,Singh, RP,Dhanalakshmi, S,Agarwal, C,Agarwal, R(2007).Silibinin inhibits inflammatory and angiogenic attributes in photocarcinogenesis in SKH-1 hairless mice.Cancer Res,67(7),3483-3491.
22. Guillermo-Lagae, R,Deep, G,Ting, H,Agarwal, C,Agarwal, R(2015).Silibinin enhances the repair of ultraviolet B-induced DNA damage by activating p53-dependent nucleotide excision repair mechanism in human dermal fibroblasts.Oncotarget,6(37),39594-39606.
23. Harwood, CA,Surentheran, T,McGregor, JM,Spink, PJ,Leigh, IM,Breuer, JPC(2000).Human papillomavirus infection and non-melanoma skin cancer in immunosuppressed and immunocompetent individuals.J Med Virol,3(61),289-297.
24. Kumar, R,Deep, G,Agarwal, R(2015).An overview of ultraviolet B radiation-induced skin cancer chemoprevention by silibinin.Curr Pharmacol Rep,1(3),206-215.
25. Lichter, MD,Karagas, MR,Mott, LA,Spencer, SK,Stukel, TA,Greenberg, ER(2000).Greenberg ER. Therapeutic ionizing radiation and the incidence of basal cell carcinoma and squamous cell carcinoma. The New Hampshire Skin Cancer Study Group.Arch Dermatol,136(8),1007-1011.
26. Liu, W,Otkur, W,Li, L(2013).Interference of silibinin with IGF-1R signalling pathways protects human epidermoid carcinoma A431 cells from UVB-induced apoptosis.Biochem Biophys Res Commun,432(2),314-319.
27. Lv, Y,Gao, S,Xu, S,Du, G,Zhou, J,Chen, J(2017).Spatial organization of silybin biosynthesis in milk thistle [ Silybum marianum (L.) Gaertn].Plant J,92(6),995-1004.
28. Madan, V,Lear, JT,Szeimies, RM(2010).Non-melanoma skin cancer.Lancet,375(9715),673-685.
29. Mahindroo, N,Punchihewa, C,Fujii, N(2009).Hedgehog-Gli signaling pathway inhibitors as anticancer agents.J Med Chem.,52(13),3829-3845.
30. Mallikarjuna, G,Dhanalakshmi, S,Singh, RP,Agarwal, C,Agarwal, R(2004).Silibinin protects against photocarcinogenesis via modulation of cell cycle regulators, mitogen-activated protein kinases, and Akt signaling.Cancer Res,64(17),6349-6356.
31. Mcallister, F,Kolls, JK(2015).Th17 cytokines in non-melanoma skin cancer.Eur J Immunol,45(3),692-694.
32. Mengs, U,Torsten Pohl, R,Mitchell, T(2012).Legalon® SIL: the antidote of choice in patients with acute hepatotoxicity from amatoxin poisoning.Curr Pharmaceut Biotechnol,13(10),1964-1970.
33. Mukhtar, H,Elmets, CA(1996).Photocarcinogenesis: mechanisms, models and human health implications.Photochem Photobiol,63(4),356-357.
34. Ng, CY,Yen, H,Hsiao, HY,Su, SC(2018).Phytochemicals in skin cancer prevention and treatment: an updated review.Int J Mol Sci.,19(4)
35. Nichols, JA,Katiyar, SK(2010).Skin photoprotection by natural polyphenols: anti-inflammatory, antioxidant and DNA repair mechanisms.Arch Dermatol Res.,302(2),71-83.
36. Pellegrini, C,Maturo, MG,Di Nardo, L,Ciciarelli, V,Gutiérrez García-Rodrigo, C,Fargnoli, MC(2017).Understanding the molecular genetics of basal cell carcinoma.Int J Mol Sci.,18(11),1-16.
37. Petruseva, IO,Evdokimov, AN,Lavrik, OI(2014).Molecular mechanism of global genome nucleotide excision repair.Acta Nat,6(20),23-34.
38. Pickering, CR,Zhou, JH,Lee, JJ(2014).Mutational landscape of aggressive cutaneous squamous cell carcinoma.Clin Canc Res,20(24),6582-6592.
39. Proctor, AE,Thompson, LA,O’Bryant, CL(2014).Vismodegib: an inhibitor of the hedgehog signaling pathway in the treatment of basal cell carcinoma.Ann Pharmacother,48(1),99-106.
40. Ramawat, KG(ed.),Merillon, JM(ed.)(2008).Bioactive Molecules and Medicinal Plants.Berlin, Heidelberg:Springer.
41. Rigby, C,Deep, G,Jain, A,Orlicky, DJ,Agarwal, C,Agarwal, R(2019).Silibinin inhibits ultraviolet B radiation-induced mast cells recruitment and bone morphogenetic protein 2 expression in the skin at early stages in Ptch(+/-) mouse model of basal cell carcinoma.Mol Carcinog,58(7),1260-1271.
42. Rigby, CM,Roy, S,Deep, G(2017).Role of p53 in silibinin-mediated inhibition of ultraviolet B radiation-induced DNA damage, inflammation and skin carcinogenesis.Carcinogenesis,38(1),40-50.
43. Rogers, HW,Weinstock, MA,Feldman, SR,Coldiron, BM(2015).Incidence estimate of nonmelanoma skin cancer (keratinocyte carcinomas) in the us population, 2012.JAMA Dermatol,151(10),1081-1086.
44. Rubin, H.(2011).Fields and field cancerization: the preneoplastic origins of cancer: asymptomatic hyperplastic fields are precursors of neoplasia, and their progression to tumors can be tracked by saturation density in culture.Bioessays,33(3),224-231.
45. Samarasinghe, V,Madan, V,Lear, JT(2011).Focus on basal cell carcinoma.J Skin Cancer,2011,1-5.
46. Sekulic, A,Migden, MR,Oro, AE(2012).Efficacy and safety of vismodegib in advanced basal-cell carcinoma.N Engl J Med.,366(23),2171-2179.
47. Siegel, RL,Miller, KD,Jemal, A(2019).Cancer statistics, 2019.CA A Cancer J Clin,69(1),7-34.
48. Singh, B,Reddy, PG,Goberdhan, A(2002).p53 regulates cell survival by inhibiting PIK3CA in squamous cell carcinomas.Genes Dev,16(8),984-993.
49. Singh, RP,Agarwal, R.(2005).Mechanisms and preclinical efficacy of silibinin in preventing skin cancer.Eur J Canc.,41(13),1969-1979.
50. Singh, RP,Tyagi, AK,Zhao, J,Agarwal, R.(2002).Silymarin inhibits growth and causes regression of established skin tumors in SENCAR mice via modulation of mitogen-activated protein kinases and induction of apoptosis.Carcinogenesis,23(3),499-510.
51. Smith, WA,Lauren, DR,Burgess, EJ,Perry, NB,Martin, RJ(2005).A silychristin isomer and variation of flavonolignan levels in milk thistle (Silybum marianum) fruits.Planta Med,71(9),877-880.
52. Sugasawa, K.(2008).Xeroderma pigmentosum genes: functions inside and outside DNA repair.Carcinogenesis,29(3),455-465.
53. Tamayo, C,Diamond, S(2007).Review of clinical trials evaluating safety and efficacy of milk thistle (Silybum marianum [L.] Gaertn.).Integr Canc Ther,6(2),146-157.
54. Tilley, C,Deep, G,Agarwal, C(2016).Silibinin and its 2,3-dehydro-derivative inhibit basal cell carcinoma growth via suppression of mitogenic signaling and transcription factors activation.Mol Carcinog,55(1),3-14.
55. Wagner, H,Diesel, P,Seitz, M(1974).The chemistry and analysis of silymarin from Silybum marianum Gaertn.Arzneimittelforschung,24(4),466-471.
56. Wagner, H,Hörhammer, L,Münster, R(1968).On the chemistry of silymarin (silybin), the active principle of the fruits from Silybum marianum (L.) Gaertn. (Carduus marianus L.).Arzneimittelforschung,18(6),688-696.
57. Wang, GY,Wang, J,Mancianti, ML,Epstein, EH(2011).Basal cell carcinomas arise from hair follicle stem cells in Ptch1+/- mice.Canc Cell,19(1),114-124.
58. Wang, Q,Ye, Y,Liu, W(2012).Dual effects of silibinin treatment on autophagyregulated dermal apoptosis retardation and epidermal apoptosis upregulation in UVB-induced skin inflammation.J Asian Nat Prod Res.,14(7),688-699.
59. Watson, M,Holman, DM,Maguire-Eisen, M(2016).Ultraviolet radiation exposure and its impact on skin cancer risk.Semin Oncol Nurs,32(3),241-254.
60. Zanetti, R,Rosso, S,Martinez, C(2006).Comparison of risk patterns in carcinoma and melanoma of the skin in men: a multi-centre case-case-control study.Br J Canc,94(5),743-751.
61. Zhang, M,Qureshi, AA,Geller, AC,Frazier, L,Hunter, DJ,Han, J(2012).Use of tanning beds and incidence of skin cancer.J Clin Oncol,30(14),1588-1593.
62. Zhao, J,Agarwal, R(1999).Tissue distribution of silibinin, the major active constituent of silymarin, in mice and its association with enhancement of phase II enzymes: implications in cancer chemoprevention.Carcinogenesis,20(11),2101-2108.
63. Zhao, J,Lahiri-Chatterjee, M,Sharma, Y,Agarwal, R(2000).Inhibitory effect of a flavonoid antioxidant silymarin on benzoyl peroxide-induced tumor promotion, oxidative stress and inflammatory responses in SENCAR mouse skin.Carcinogenesis,21(4),811-816.
64. Zhao, J,Sharma, Y,Agarwal, R(1999).Significant inhibition by the flavonoid antioxidant silymarin against 12-O-tetradecanoylphorbol 13-acetate-caused modulation of antioxidant and inflammatory enzymes, and cyclooxygenase 2 and interleukin-1? expression in SENCAR mouse epidermis: Implication.Mol Carcinog,26(4),321-333.
65. Zi, X,Mukhtar, H,Agarwal, R(1997).Novel cancer chemopreventive effects of a flavonoid antioxidant silymarin: inhibition of mRNA expression of an endogenous tumor promoter TNFa.Biochem Biophys Res Commun,239(1),334-339.